News
Keyword Search
04/15/24
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
04/11/24
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
04/10/24
Aptevo Therapeutics Provides Pipeline Update
03/18/24
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
03/07/24
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
03/05/24
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
03/04/24
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan